NEWS AND VIEWS FROM THE PHARMACEUTICAL FINE CHEMICAL AND CUSTOM MANUFACTURING SECTOR

Tuesday 1 September 2009

Patheon continues to explore Lonza bid

Patheon's independent directors are continuing to examine Lonza's bid for the company. The Lonza offer, which is a 77% premium over that of JLL is conditional on being able to secure two-thirds of Patheon's shares.
Patheon

No comments: